The Nonantibiotic Macrolide EM900 Attenuates House Dust Mite-Induced Airway Inflammation in a Mouse Model of Obesity-Associated Asthma
- 29 June 2020
- journal article
- research article
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 181 (9), 665-674
- https://doi.org/10.1159/000508709
Abstract
Introduction: Obesity-associated asthma is characterized by type 2-low airway inflammation. We previously showed that EM900, which is a 12-membered nonantibiotic macrolide, suppressed airway inflammation in a mouse model of asthma exacerbation. The aim of this study was to clarify the effects of EM900 in obesity-associated asthma. Methods: BALB/c mice were fed a low-fat diet (LFD) or high-fat diet (HFD). Mice were intranasally sensitized and challenged with house dust mites (HDMs) and were orally administered EM900. Airway inflammation was assessed using inflammatory cells in bronchoalveolar lavage (BALF). Cytokines were examined by ELISA in lung tissues. Lung interstitial macrophages (CD45+, CD11clow, CD11b+, and Ly6c−) were counted by flow cytometry in single cells from lung tissues. Results: Body weight increased significantly in the HFD compared with the LFD group. The total cell count and numbers of neutrophils and eosinophils in BALF were significantly suppressed by EM900 administration in the HFD-HDM group. The levels of interleukin (IL)-17A were increased in the HFD-HDM group compared with the LFD-HDM group, although the difference did not reach statistical significance. The levels of IL-17A, macrophage inflammatory protein 2, IL-1β, IL-5, and regulated on activation, normal T cell expressed and secreted in lung tissue were significantly suppressed by EM900 administration in the HFD-HDM group. The percentage of interstitial macrophages in lungs was significantly decreased by EM900 administration in the HFD-HDM group. Conclusion: Both type 2 and type 2-low airway inflammation were attenuated by EM900 in this obesity-associated asthma model. These results show that EM900 might be a candidate agent for the treatment of obesity-associated asthma.Keywords
This publication has 46 references indexed in Scilit:
- Novel 12-membered non-antibiotic macrolides from erythromycin A; EM900 series as novel leads for anti-inflammatory and/or immunomodulatory agentsBioorganic & Medicinal Chemistry Letters, 2011
- Airway inflammation is augmented by obesity and fatty acids in asthmaEuropean Respiratory Journal, 2011
- Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe AsthmaJournal of Allergy and Clinical Immunology, 2010
- Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research ProgramAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Effects of omalizumab on markers of inflammation in patients with allergic asthmaAllergy, 2009
- Macrophage CD74 contributes to MIF-induced pulmonary inflammationRespiratory Research, 2009
- Inhibition of cAMP Degradation Improves Regulatory T Cell-Mediated SuppressionThe Journal of Immunology, 2009
- A protein associated with Toll-like receptor (TLR) 4 (PRAT4A) is required for TLR-dependent immune responsesThe Journal of Experimental Medicine, 2007
- Obesity and asthmaPharmacology & Therapeutics, 2006
- Bacterial Resistance: Origins, Epidemiology, and ImpactClinical Infectious Diseases, 2003